AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. The British pharma—which sells Lynparza as a prostate cancer treatment and is also testing its ...

A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A stra ze neca,” means “a road to death” in Latin. We reached out to ...

Country music star Reba McEntire hosted the 60th annual ACM Awards for the 18th time Thursday in Frisco, Texas. Old Dominion won group of the year and Morgan Wallen skipped the show.

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to attack cancer.Soon, Maryland will be home to one of the largest facilities ...

AstraZeneca's patents covering Soliris should have expired in 2021, but the company misled the U.S. Patent and Trademark Office to obtain more patents with expiration dates "well into the future ...

The global biopharmaceutical company, which focuses on drug discovery, development and commercialization, in association with Scientific American Custom Media, and as part of the AstraZeneca YOUR ...

AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities ...

AstraZeneca's improving financial position isn't yet fully reflected in its stock price AstraZeneca's revenue was about $13.57 billion in the third quarter of 2024, up 18.1% year-over-year and 4. ...